Allergy Immunotherapy Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The allergy immunotherapy market was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.

Allergy immunotherapy is a preventative treatment for allergies that aims to mitigate the severity of allergic reactions to specific allergens such as house dust mites, bee venom, and grass pollens. This therapy involves gradual increase in administration of doses of the allergen to which an individual is allergic, thus making the immune systems less sensitive to the allergen and reducing the symptoms of allergy. The therapy can lead to long-term relief and decreased dependence on allergy medications.

The growth of the global allergy immunotherapy market is majorly driven by alarming rise in the prevalence of allergic conditions such as allergic rhinitis, asthma, and food allergies coupled with increase in awareness about allergy immunotherapy among patients and healthcare providers. Based on a 2011 study published in the White Book on Allergy, the prevalence rate of allergic rhinitis from 1% to 18%, skin allergies from 2% to 10%, and asthma ranges from 1% to 20% in various populations. Moreover, increase in preference of patients for effective and long-term solutions to allergy management fosters the demand for allergy immunotherapy, which significantly contributes toward the growth of the market. Furthermore, increase in trend toward personalized medicine is driving the demand for tailored immunotherapy treatments that address individual patient needs and specific allergies, which fosters the market growth. However, high cost of the associated with allergy immunotherapy and increase in concerns about the side effects of the treatment act as the key deterrent factors of the market. On the contrary, increase in healthcare expenditure in emerging markets is facilitating the access to advanced treatments like allergy immunotherapy, which is expected to offer remunerative opportunities for the growth of the market during the forecast period. Moreover, advancements in immunotherapy techniques, such as the development of sublingual immunotherapy and improved formulations of subcutaneous immunotherapy, are making treatments more effective and accessible, which are expected to open new avenues for the market growth.

The global allergy immunotherapy market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into subcutaneous immunotherapy and sublingual immunotherapy. By application, it is segregated into allergy rhinitis, asthma, food allergy, and others. Depending on distribution channel, it is fragmented into hospital pharmacies, retail, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.

By application, the allergic rhinitis segment is expected to exhibit highest growth rate by 2033.

Depending on distribution channel,, the hospital pharmacies segment is anticipated to gain high prominence during the forecast period.

Region wise, North America is projected to dominate the allergy immunotherapy market in the coming years.

Competition Analysis

Competitive analysis and profiles of the major players in the global allergy immunotherapy market include Torii Pharmaceutical Co., Ltd., Biomay AG, ALK-Abello A/S, Allergy Therapeutics, Allovate, LLC, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, and Stallergenes Greer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and garner a strong foothold in the global market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Reimbursement Scenario

Key Market Segments

By Type

Subcutaneous Immunotherapy
Sublingual Immunotherapy

By Application

Allergy Rhinitis
Asthma
Food Allergy
Others

By Distribution Channel

Hospital Pharmacies
Retail
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Torii Pharmaceutical Co., Ltd.
Biomay AG
ALK-Abello A/S
Allergy Therapeutics
Allovate, LLC
HAL Allergy Group
Jubliant Pharma
Leti Pharma
Merck KGaA
Stallergenes Greer

Product Code: A10241

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Subcutaneous Immunotherapy
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Sublingual Immunotherapy
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
5.2. Allergy Rhinitis
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Asthma
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Food Allergy
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
5.5. Others
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country

CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Retail
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Online Pharmacies
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Allergy Immunotherapy Market
  - 7.2.6.1. Market Size and Forecast, By Type
  - 7.2.6.2. Market Size and Forecast, By Application
  - 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Allergy Immunotherapy Market
  - 7.2.7.1. Market Size and Forecast, By Type
  - 7.2.7.2. Market Size and Forecast, By Application
  - 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Allergy Immunotherapy Market
  - 7.2.8.1. Market Size and Forecast, By Type
  - 7.2.8.2. Market Size and Forecast, By Application
  - 7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Allergy Immunotherapy Market
  - 7.3.6.1. Market Size and Forecast, By Type
  - 7.3.6.2. Market Size and Forecast, By Application
  - 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Allergy Immunotherapy Market
  - 7.3.7.1. Market Size and Forecast, By Type
  - 7.3.7.2. Market Size and Forecast, By Application
  - 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Allergy Immunotherapy Market
  - 7.3.8.1. Market Size and Forecast, By Type
  - 7.3.8.2. Market Size and Forecast, By Application
  - 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Allergy Immunotherapy Market
  - 7.3.9.1. Market Size and Forecast, By Type
  - 7.3.9.2. Market Size and Forecast, By Application
  - 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Allergy Immunotherapy Market
  - 7.3.10.1. Market Size and Forecast, By Type
  - 7.3.10.2. Market Size and Forecast, By Application
  - 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest of Europe Allergy Immunotherapy Market
  - 7.3.11.1. Market Size and Forecast, By Type
  - 7.3.11.2. Market Size and Forecast, By Application
  - 7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Allergy Immunotherapy Market
  - 7.4.6.1. Market Size and Forecast, By Type
  - 7.4.6.2. Market Size and Forecast, By Application
  - 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Allergy Immunotherapy Market
  - 7.4.7.1. Market Size and Forecast, By Type
  - 7.4.7.2. Market Size and Forecast, By Application
  - 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Allergy Immunotherapy Market
  - 7.4.8.1. Market Size and Forecast, By Type
  - 7.4.8.2. Market Size and Forecast, By Application
  - 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Allergy Immunotherapy Market
  - 7.4.9.1. Market Size and Forecast, By Type
  - 7.4.9.2. Market Size and Forecast, By Application
  - 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Allergy Immunotherapy Market
  - 7.4.10.1. Market Size and Forecast, By Type
  - 7.4.10.2. Market Size and Forecast, By Application
  - 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Allergy Immunotherapy Market
  - 7.4.11.1. Market Size and Forecast, By Type
  - 7.4.11.2. Market Size and Forecast, By Application
  - 7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Allergy Immunotherapy Market
  - 7.5.6.1. Market Size and Forecast, By Type
  - 7.5.6.2. Market Size and Forecast, By Application
  - 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Allergy Immunotherapy Market
  - 7.5.7.1. Market Size and Forecast, By Type
  - 7.5.7.2. Market Size and Forecast, By Application
  - 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Allergy Immunotherapy Market
  - 7.5.8.1. Market Size and Forecast, By Type
  - 7.5.8.2. Market Size and Forecast, By Application
  - 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Allergy Immunotherapy Market
  - 7.5.9.1. Market Size and Forecast, By Type
  - 7.5.9.2. Market Size and Forecast, By Application
  - 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Torii Pharmaceutical Co., Ltd.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Biomay AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. ALK-Abello A/S
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Allergy Therapeutics
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Allovate, LLC
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. HAL Allergy Group
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Jubliant Pharma
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Leti Pharma
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Merck KGaA
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Stallergenes Greer
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments